SEHK:2696Biotechs
Shanghai Henlius Biotech (SEHK:2696) Valuation Check After Strong 1 Year Total Shareholder Return
Shanghai Henlius Biotech (SEHK:2696) has caught investor attention after a strong 1 year total return of 144%, alongside revenue of CN¥5,797.88 and net income of CN¥824.30, prompting closer scrutiny of its valuation.
See our latest analysis for Shanghai Henlius Biotech.
Despite a recent 7 day share price return of 7.2% decline and some short term volatility, Shanghai Henlius Biotech’s 1 year total shareholder return of 144.26% and very large 3 year total shareholder return suggest momentum...